Study populations CANVAS Program The CANVAS Program, which integrated the CANVAS and CANVAS-R trials, investigated the effects of canagliflozin on CV, renal and safety outcomes in 10,142 patients with T2D and either established CV disease or at high CV risk, with a mean follow-up time of 188 weeks. Details of the CANVAS Program design have been published [11, 12].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile